EDIT
Editas Medicine Inc.
Is EDIT Halal?
CRISPR gene editing — similar ethical considerations.
What You Should Know
Develops CRISPR therapies for inherited diseases. Pre-revenue clinical stage. Its March 31, 2026 Form 10-Q reports $149.338 million of assets, $71.974 million of conservative debt and leases, $123.648 million of cash, $123.648 million of identified debt securities, $2.592 million of receivables and $2.831 million of quarterly revenue. Debt/assets is 48.20%, liquidity/assets is 165.58%, receivables-plus-cash/assets is 84.46% and disclosed investment income is 42.60% of revenue; the examined financial screens fail. Gene editing requires case-by-case fatwa.
⚠️ Concerns
- •Ethical uncertainty
- •Pre-revenue risk
- •Debt and liquidity screens fail
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
71.974 / 149.338
247.296 / 149.338
126.24 / 149.338
1.206 / 2.831
- Financial
- Fails
- Overall
- Fails
Debt/assets is 48.20%, liquidity/assets is 165.58%, receivables-plus-cash/assets is 84.46% and disclosed investment income is 42.60%; each relevant examined limit is exceeded.
- Financial
- Fails
- Overall
- Fails
Debt/assets, liquidity/assets and receivables-plus-cash/assets are above the examined MSCI total-assets limits.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 48.20% and liquidity/assets is 165.58%, above the examined Malaysia 33% limits. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Editas develops CRISPR gene-editing therapies for inherited disease. Therapeutic healthcare is generally permissible, while gene-editing boundaries, licensing and product allocation require qualified scholarly review.
Limitation: The filing does not provide a universal prohibited-activity numerator across collaborations and therapeutic programs.
Purification
Editas discloses $1.206 million of net investment income, but no scholar-approved purification percentage is asserted for the operating business.
Inputs, assumptions and primary sources
- Amounts are USD millions from Editas Medicine's March 31, 2026 Form 10-Q.
- Conservative debt includes $54.677 million current and noncurrent debt plus $17.297 million of current and noncurrent operating-lease liabilities.
- Cash and cash equivalents and available-for-sale debt securities are each tagged at $123.648 million; the filing's presentation is retained without netting. Accounts receivable are $2.592 million.
- Quarterly revenue is $2.831 million and disclosed net investment income is $1.206 million, or 42.60% of revenue.
- Gene-editing therapeutics are generally permissible in the retained qualitative analysis, but bioethics and clinical-program allocation remain case-dependent.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →